Abstract
Symptom provocation has proved its worth for understanding the pathophysiology of diseases and in general for the development of new therapeutic approaches in the medical field. In the research of anxiety disorders, investigations using experimentally induced panic attacks by various agents, such as sodium lactate, carbon dioxide, cholezystokinine-tetrapetid etc., have a long tradition and allow the exploration of usually naturally occuring spontaneous psychopathological phenomena under controlled conditions. Post-Traumatic Stress Disorder (PTSD) is a prevalent disorder that can develop following exposure to an extreme traumatic event. In DSM-IV it is currently classified as an anxiety disorder and shares phenomenological similarities with panic disorder. The use of panicogenic challenge tests is also an interesting neurobiological approach to learn more about the nature of PTSD and may be a possibility to develop new therapeutic strategies for the treatment of PTSD symptoms. Not only panic anxiety, but also flashbacks and other dissociative symptoms can be provoked by several panicogens in PTSD. The purpose of this review is to evaluate studies using panicogens in PTSD. Methodological short-comings of current studies and needed directions of further research are discussed.
Keywords: PTSD, panic, panicogen, flashback, lactate, CCK-4, CO2, flumazenil, m-CPP, yohimbine
Current Pharmaceutical Design
Title:Panicogens in Patients with Post-Traumatic Stress Disorder (PTSD)
Volume: 18 Issue: 35
Author(s): Christoph Muhtz, Klaus Wiedemann and Michael Kellner
Affiliation:
Keywords: PTSD, panic, panicogen, flashback, lactate, CCK-4, CO2, flumazenil, m-CPP, yohimbine
Abstract: Symptom provocation has proved its worth for understanding the pathophysiology of diseases and in general for the development of new therapeutic approaches in the medical field. In the research of anxiety disorders, investigations using experimentally induced panic attacks by various agents, such as sodium lactate, carbon dioxide, cholezystokinine-tetrapetid etc., have a long tradition and allow the exploration of usually naturally occuring spontaneous psychopathological phenomena under controlled conditions. Post-Traumatic Stress Disorder (PTSD) is a prevalent disorder that can develop following exposure to an extreme traumatic event. In DSM-IV it is currently classified as an anxiety disorder and shares phenomenological similarities with panic disorder. The use of panicogenic challenge tests is also an interesting neurobiological approach to learn more about the nature of PTSD and may be a possibility to develop new therapeutic strategies for the treatment of PTSD symptoms. Not only panic anxiety, but also flashbacks and other dissociative symptoms can be provoked by several panicogens in PTSD. The purpose of this review is to evaluate studies using panicogens in PTSD. Methodological short-comings of current studies and needed directions of further research are discussed.
Export Options
About this article
Cite this article as:
Muhtz Christoph, Wiedemann Klaus and Kellner Michael, Panicogens in Patients with Post-Traumatic Stress Disorder (PTSD), Current Pharmaceutical Design 2012; 18 (35) . https://dx.doi.org/10.2174/138161212803530817
DOI https://dx.doi.org/10.2174/138161212803530817 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Safety Analysis and Improved Cardiac Function Following Local Autologous Transplantation of CD133+ Enriched Bone Marrow Cells After Myocardial Infarction
Current Neurovascular Research Biological Evaluation of 8-Hydroxyquinolines as Multi-Target Directed Ligands for Treating Alzheimer’s Disease
Current Alzheimer Research Alzheimer’s Disease: Physical Activities as an Effective Intervention Tool - A Mini-Review
Current Alzheimer Research Neuritin, A Neurotrophic Factor in Nervous System Physiology
Current Medicinal Chemistry Convolutional Neural Network Visualization for Identification of Risk Genes in Bipolar Disorder
Current Molecular Medicine Myocardial Revascularization for the Elderly: Current Options, Role of Off-pump Coronary Artery Bypass Grafting and Outcomes
Current Cardiology Reviews Patent Selections:
Current Biomarkers (Discontinued) Alzheimer’s Disease Drugs- In Vitro Comparison of Cholinesterase Inhibition and beta-amyloid Modulation
Letters in Drug Design & Discovery New Poly(3-hydroxybutyrate) Microparticles with Paclitaxel Sustained Release for Intraperitoneal Administration
Anti-Cancer Agents in Medicinal Chemistry The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology Biological Therapies in Osteoarthritis
Current Pharmaceutical Design Magnetic Resonance Imaging of Short T2 Relaxation Components in Tissue Using Ultrashort Echo Time (UTE) Pulse Sequences
Current Medical Imaging Medical Treatment of Malignancy-Associated Hypercalcemia
Current Medicinal Chemistry Commentary-2 Research Highlights: (Adult-Born Neurons with Unique GABAergic Synapses)
CNS & Neurological Disorders - Drug Targets Structural and Aggregation Properties of Alpha-Synuclein Linked to Phospholipase A2 Action
Protein & Peptide Letters Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology Pharmacological Therapy in Children with Atrioventricular Reentry: Which Drug?
Current Pharmaceutical Design Paullones as Inhibitors of Protein Kinases
Current Topics in Medicinal Chemistry Pleiotropic Effects of Cytokines on Acute Myocardial Infarction: G-CSF as A Novel Therapy for Acute Myocardial Infarction
Current Pharmaceutical Design Targeted Blockade of TARP-γ8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611)
CNS & Neurological Disorders - Drug Targets